ClinicalTrials.gg
Not yet recruitingNCT07805447DPBT-AVRIUpdated Sep 4, 2026

Botanical Therapy for Acute Viral Respiratory Infections

A Phase 1 interventional study of PurInf I Botanical Formulation and PurInf II Botanical Formulation in Acute Viral Respiratory Infection, sponsored by All Natural Medicine Clinic, LLC. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by All Natural Medicine Clinic, LLC · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This Phase 1 study will evaluate the feasibility and safety of implementing a host pathologic state-directed botanical therapeutic platform in adults with acute viral respiratory infections. The platform, called Dynamic Pathology-Based Therapy (DPBT), uses a predefined clinical algorithm to identify participants' pathological states and select the corresponding botanical formulation module or combination of modules.

Approximately 30 adults aged 18 to 80 will participate in this prospective, single-group, open-label study. All participants will receive the assigned DPBT intervention in addition to medically appropriate standard care. Treatment will generally continue for 7 days and may be extended through Day 10 if predefined pathological states persist. Study assessments will examine protocol implementation, recruitment and retention, adherence, treatment tolerability, adverse events, changes in symptoms and recovery, and exploratory changes in viral detection through Day 12.

Read the detailed description

This Phase 1 study is a prospective, single-group, open-label feasibility study enrolling approximately 30 adults aged 18 to 80 with acute viral respiratory infections. The study will evaluate the feasibility and safety of implementing a host pathologic state-directed botanical therapeutic platform using a predefined Dynamic Pathology-Based Therapy (DPBT) clinical algorithm.

DPBT is designed to select treatment according to predefined host pathological states rather than solely according to viral identity. Eligible infections may include influenza, respiratory syncytial virus, COVID-19, adenovirus, parainfluenza virus, human metapneumovirus, rhinovirus, or another clinically compatible acute viral respiratory infection. Viral identification testing will be performed when feasible and medically appropriate.

At baseline, participants will undergo eligibility assessment, clinical evaluation, characterization of predefined pathological states, and viral identification testing. Based on each participant's presenting pathological state or combination of states, the corresponding botanical formulation module or combination of modules will be assigned according to the predefined DPBT treatment algorithm. All participants will receive the study intervention in addition to medically appropriate standard care.

Treatment will generally continue for 7 days. Participants will be clinically reassessed during treatment and on Day 7. If predefined pathological states persist, treatment may be extended through Days 8 to 10 according to the protocol. Follow-up viral identification testing will be performed on Day 12 when a respiratory virus was detected at baseline, and repeat testing is feasible.

The primary objectives are to assess the feasibility of implementing the DPBT clinical algorithm and to evaluate safety and tolerability. Feasibility assessments will include recruitment, retention, protocol adherence, completion of required assessments, correct application of the treatment algorithm, and completeness of study data. Safety assessments will include adverse events, serious adverse events, treatment interruptions, discontinuations, and clinical tolerability.

Exploratory assessments will examine changes in respiratory and systemic symptoms, fever, oral intake, activity level, need for additional medical care, return to usual function, and viral detection. Because this is a small, single-group feasibility study, it is not designed or statistically powered to establish definitive efficacy or to compare outcomes among different respiratory viruses.

02

Conditions studied

  • Acute Viral Respiratory Infection

Keywords

  • Dynamic Pathology-Based Therapy
  • DPBT
  • Host Pathology-Directed Therapy
  • Botanical Therapy
  • Botanical Medicine
  • Acute Viral Respiratory Infection
  • Host-Directed Therapy
  • Respiratory Virus
03

In context

Lead sponsor

All Natural Medicine Clinic, LLC is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-80 years.
  • Presence of an acute viral respiratory infection or clinical presentation consistent with an acute viral respiratory infection.
  • Onset of acute respiratory symptoms within a predefined period before enrollment.
  • Presence of one or more predefined pathological states eligible for treatment according to the DPBT clinical algorithm.
  • Able and willing to comply with study treatment, clinical assessments, and viral testing.
  • Able to understand the study requirements and provide written .

Exclusion criteria

Exclusion Criteria

  • Severe or life-threatening illness requiring immediate hospitalization or emergency medical treatment at enrollment.
  • Known allergy, , or intolerance to any ingredient in the botanical formulations that may be administered.
  • Pregnancy or breastfeeding.
  • Significant medical condition that, in the investigator's judgment, would make participation unsafe or interfere with interpretation of study outcomes.
  • Current participation in another interventional clinical trial that could interfere with this study.
  • Unable or unwilling to comply with study procedures or provide .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    DPBT Botanical Therapy

    Participants in this single experimental arm will receive host pathologic state-directed botanical therapy using the predefined Dynamic Pathology-Based Therapy (DPBT) clinical algorithm, in addition to medically appropriate standard care. Based on the participant's presenting pathological state or combination of states, the algorithm will assign one or more of six botanical formulation modules: PurInf I for an upper-respiratory inflammatory state, PurInf II for a fever-predominant state, PurInf III for a lower-respiratory inflammatory state, PurCo for a cough-predominant state, PurPhl for a pathological-secretions state, and PurClo for a clot- and poor-circulation-related state. Assigned modules may be continued, added, removed, or discontinued according to protocol-defined reassessment. Treatment will generally continue for 7 days and may be extended through Day 10 if predefined pathological states persist.

    Drug: PurInf I Botanical Formulation · Drug: PurInf II Botanical Formulation · Drug: PurInf III Botanical Formulation · Drug: PurCo Botanical Formulation · Drug: PurPhl Botanical Formulation · Drug: PurClo Botanical Formulation

Interventions

  • DrugPurInf I Botanical Formulation

    A proprietary oral multi-ingredient botanical formulation module assigned through the predefined DPBT clinical algorithm for participants with an upper respiratory inflammatory pathological state. PurInf I may be administered alone or in combination with other DPBT formulation modules according to protocol-defined assessment and reassessment. Treatment will generally continue for 7 days and may be extended through Day 10 if the corresponding pathological state persists. Administration, adherence, treatment modification, interruption, and discontinuation will be documented according to the study protocol.

  • DrugPurInf II Botanical Formulation

    A proprietary oral multi-ingredient botanical formulation module assigned through the predefined DPBT clinical algorithm for participants with a fever-predominant pathological state. PurInf II may be administered alone or in combination with other DPBT formulation modules according to protocol-defined assessment and reassessment. Treatment will generally continue for 7 days and may be extended through Day 10 if the corresponding pathological state persists. Administration, adherence, treatment modification, interruption, and discontinuation will be documented according to the study protocol.

  • DrugPurInf III Botanical Formulation

    A proprietary oral multi-ingredient botanical formulation module assigned through the predefined DPBT clinical algorithm for participants with a lower respiratory inflammatory pathological state. PurInf III may be administered alone or in combination with other DPBT formulation modules according to protocol-defined assessment and reassessment. Treatment will generally continue for 7 days and may be extended through Day 10 if the corresponding pathological state persists. Administration, adherence, treatment modification, interruption, and discontinuation will be documented according to the study protocol.

  • DrugPurCo Botanical Formulation

    A proprietary oral multi-ingredient botanical formulation module assigned through the predefined DPBT clinical algorithm for participants with a cough-predominant pathological state. PurCo may be administered alone or in combination with other DPBT formulation modules according to protocol-defined assessment and reassessment. Treatment will generally continue for 7 days and may be extended through Day 10 if the corresponding pathological state persists. Administration, adherence, treatment modification, interruption, and discontinuation will be documented according to the study protocol.

  • DrugPurPhl Botanical Formulation

    A proprietary oral multi-ingredient botanical formulation module assigned through the predefined DPBT clinical algorithm for participants with a pathological-secretions state. PurPhl may be administered alone or in combination with other DPBT formulation modules according to protocol-defined assessment and reassessment. Treatment will generally continue for 7 days and may be extended through Day 10 if the corresponding pathological state persists. Administration, adherence, treatment modification, interruption, and discontinuation will be documented according to the study protocol.

  • DrugPurClo Botanical Formulation

    A proprietary oral multi-ingredient botanical formulation module assigned through the predefined DPBT clinical algorithm for participants with a clot- and poor-circulation-related pathological state. PurClo may be administered alone or in combination with other DPBT formulation modules according to protocol-defined assessment and reassessment. Treatment will generally continue for 7 days and may be extended through Day 10 if the corresponding pathological state persists. Administration, adherence, treatment modification, interruption, and discontinuation will be documented according to the study protocol.

06

What researchers measure

Primary outcomes

  1. Feasibility of DPBT Protocol Implementation

    Proportion of enrolled participants who complete the assigned DPBT treatment and required study assessments according to the protocol.

    Time frame: Through Day 12

  2. Safety and Tolerability of DPBT Treatment

    Number and proportion of participants experiencing adverse events and serious adverse events, including treatment-related adverse events, treatment interruptions, and treatment discontinuations.

    Time frame: Day 0 through Day 12

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the reported study results may be shared with qualified researchers following publication of the primary study results, consistent with participant informed consent, applicable privacy protections, IRB requirements, and NIH data-sharing policies. Shared data will not contain information that directly identifies individual participants.

Supporting information: Study protocol

Time frame: Beginning 6 months after publication of the primary study results and available for 5 years.

Access criteria: De-identified individual participant data will be made available to qualified researchers upon reasonable request. Requests should include a research proposal describing the intended use of the data and will be reviewed for scientific purpose and compliance with participant consent, privacy protections, and applicable IRB requirements. Data will be provided following approval of the request and, when appropriate, execution of a data use agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2027; primary completion for Jun 2028, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2026
First posted
Sep 4, 2026
StartEst.
Jul 1, 2027
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jun 30, 2028
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07805447
Lead sponsor
All Natural Medicine Clinic, LLC
Responsible party
Sponsor
First posted
Sep 4, 2026
Start date
Jul 1, 2027 (estimated)
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Sep 4, 2026

Study contacts

Wanzhu Hou, l.Ac., CH, CMD, MD(CN)
Contact
TCM@anmedicine.com
1(301)770-4480
Wanzhu Hou, L.Ac., CH., CMD, MD (CN)
principal investigator · All Natural Medicine Clinic, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion